Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2015 | Review Article

Image-derived biomarkers and multimodal imaging strategies for lung cancer management

Authors: Alexander W. Sauter, Nina Schwenzer, Mathew R. Divine, Bernd J. Pichler, Christina Pfannenberg

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2015

Abstract

Non-small-cell lung cancer is the most common type of lung cancer and one of the leading causes of cancer-related death worldwide. For this reason, advances in diagnosis and treatment are urgently needed. With the introduction of new, highly innovative hybrid imaging technologies such as PET/CT, staging and therapy response monitoring in lung cancer patients have substantially evolved. In this review, we discuss the role of FDG PET/CT in the management of lung cancer patients and the importance of new emerging imaging technologies and radiotracer developments on the path to personalized medicine.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.CrossRefPubMed

Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–9. doi:10.1002/ijc.21183.CrossRefPubMed

Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29–33. doi:10.1097/JTO.0b013e3181c5920c.CrossRefPubMed

Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S–50. doi:10.1378/chest.12-2355.CrossRefPubMed

Akin O, Brennan SB, Dershaw DD, Ginsberg MS, Gollub MJ, Schöder H, et al. Advances in oncologic imaging: update on 5 common cancers. CA Cancer J Clin. 2012;62:364–93. doi:10.3322/caac.21156.CrossRefPubMed

Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–19. doi:10.1016/s0140-6736(13)61502-0.CrossRefPubMed

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50. doi:10.1056/NEJMoa061884.CrossRefPubMed

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51. doi:10.1200/jco.2007.15.0375.CrossRefPubMed

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–9. doi:10.1200/jco.2007.13.9030.CrossRefPubMed

10.

Sause W, Kolesar P, Taylor IV S, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64.CrossRefPubMed

11.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. doi:10.1016/s1470-2045(11)70393-x.CrossRefPubMed

12.

Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109–19. doi:10.1101/gr.145144.112.CrossRefPubMedCentralPubMed

13.

Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C, Deschepper E, Dekkers OM, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010;304:2245–52. doi:10.1001/jama.2010.1705.CrossRefPubMed

14.

Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32–9. doi:10.1056/NEJMoa0900043.CrossRefPubMed

15.

Zeliadt SB, Loggers ET, Slatore CG, Au DH, Hebert PL, Klein GJ, et al. Preoperative PET and the reduction of unnecessary surgery among newly diagnosed lung cancer patients in a community setting. J Nucl Med. 2014;55:379–85. doi:10.2967/jnumed.113.124230.CrossRefPubMed

16.

Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:4–9.PubMed

17.

Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med. 2013;159:411–20. doi:10.7326/0003-4819-159-6-201309170-00690.CrossRefPubMed

18.

Walker CM, Chung JH, Abbott GF, Little BP, El-Sherief AH, Shepard JA, et al. Mediastinal lymph node staging: from noninvasive to surgical. AJR Am J Roentgenol. 2012;199:W54–64. doi:10.2214/ajr.11.7446.CrossRefPubMed

19.

Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–92.CrossRefPubMed

20.

Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7. doi:10.1056/NEJMoa022136.CrossRefPubMed

21.

Rosado-de-Christenson ML, Templeton PA, Moran CA. Bronchogenic carcinoma: radiologic-pathologic correlation. Radiographics. 1994;14:429–46. doi:10.1148/radiographics.14.2.8190965. quiz 47–8.CrossRefPubMed

22.

Sun JS, Park KJ, Sheen SS, Yoon JK, Yoon SN, Lee KB, et al. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer. 2009;66:205–10. doi:10.1016/j.lungcan.2009.01.009.CrossRefPubMed

23.

Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie. 2011;65:39–59. doi:10.1055/s-0030-1255961.CrossRefPubMed

24.

Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S–201. doi:10.1378/chest.07-1360.CrossRefPubMed

25.

Rintoul RC, Tournoy KG, El Daly H, Carroll NR, Buttery RC, van Kralingen K, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes – an international multi-centre experience. J Thorac Oncol. 2009;4:44–8. doi:10.1097/JTO.0b013e3181914357.CrossRefPubMed

26.

De Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–64.CrossRefPubMed

27.

Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;5:612–9. doi:10.1097/JTO.0b013e3181d0a4f5.PubMed

28.

Berghmans T, Paesmans M, Sculier JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011;3:127–38. doi:10.1177/1758834011401951.CrossRefPubMedCentralPubMed

29.

Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;31:3823–30. doi:10.1200/jco.2012.47.5947.CrossRefPubMedCentralPubMed

30.

Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med. 2013;54:1528–34. doi:10.2967/jnumed.112.116921.CrossRefPubMed

31.

Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I, et al. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012;18:220–8. doi:10.1158/1078-0432.CCR-11-0868.CrossRefPubMed

32.

Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, et al. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemother Pharmacol. 2014;73:299–307. doi:10.1007/s00280-013-2356-x.CrossRefPubMed

33.

Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2012;30:2731–8. doi:10.1200/jco.2011.39.4882.CrossRefPubMed

34.

Ulger S, Demirci NY, Eroglu FN, Cengiz HH, Tunc M, Tatci E, et al. High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size. J Cancer Res Clin Oncol. 2014;140:495–502. doi:10.1007/s00432-014-1591-9.CrossRefPubMed

35.

Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging. 2014;41:1057–65. doi:10.1007/s00259-014-2687-9.CrossRefPubMed

36.

Nair VS, Gevaert O, Davidzon G, Napel S, Graves EE, Hoang CD, et al. Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res. 2012;72:3725–34. doi:10.1158/0008-5472.can-11-3943.CrossRefPubMedCentralPubMed

37.

Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer. 2014;83:197–204. doi:10.1016/j.lungcan.2013.11.025.CrossRefPubMed

38.

Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3:971–8. doi:10.1097/JTO.0b013e31818307a7.CrossRefPubMed

39.

Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer. 2011;72:191–8. doi:10.1016/j.lungcan.2010.08.017.CrossRefPubMed

40.

Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96. doi:10.1007/s00259-013-2391-1.CrossRefPubMedCentralPubMed

41.

Vach W, Høilund-Carlsen PF, Gerke O, Weber WA. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med. 2011;52 Suppl 2:77S–85. doi:10.2967/jnumed.110.085704.CrossRefPubMed

42.

Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275–82.PubMed

43.

Chen L, Zhang J, Bao J, Zhang L, Hu X, Xia Y, et al. Meta-analysis of diffusion-weighted MRI in the differential diagnosis of lung lesions. J Magn Reson Imaging. 2013;37:1351–8. doi:10.1002/jmri.23939.CrossRefPubMed

44.

Koyama H, Ohno Y, Nishio M, Takenaka D, Yoshikawa T, Matsumoto S, et al. Diffusion-weighted imaging vs STIR turbo SE imaging: capability for quantitative differentiation of small-cell lung cancer from non-small-cell lung cancer. Br J Radiol. 2014;87:20130307. doi:10.1259/bjr.20130307.CrossRefPubMed

45.

Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, Umphrey H, et al. Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. J Magn Reson Imaging. 2014;39:1588–94. doi:10.1002/jmri.24319.CrossRefPubMed

46.

Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, Claussen CD, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol. 2009;193:W301–7. doi:10.2214/AJR.08.2289.CrossRefPubMed

47.

Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10:254–9.CrossRefPubMed

48.

Sourbron SP, Buckley DL. Classic models for dynamic contrast-enhanced MRI. NMR Biomed. 2013;26:1004–27. doi:10.1002/nbm.2940.CrossRefPubMed

49.

Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012;36:387–96. doi:10.1002/jmri.23660.CrossRefPubMed

50.

Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res. 2002;8:2109–15.PubMed

51.

Kramer GM, Yaqub M, Bahce I, Smit EF, Lubberink M, Hoekstra OS, et al. CT-perfusion versus [(15)O]H2O PET in lung tumors: effects of CT-perfusion methodology. Med Phys. 2013;40:052502. doi:10.1118/1.4798560.CrossRefPubMed

52.

Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol. 2000;7:840–50.CrossRefPubMed

53.

Haberland U, Klotz E, Abolmaali N. Performance assessment of dynamic spiral scan modes with variable pitch for quantitative perfusion computed tomography. Investig Radiol. 2010;45:378–86. doi:10.1097/RLI.0b013e3181dfda9f.

54.

Ma SH, Le HB, Jia BH, Wang ZX, Xiao ZW, Cheng XL, et al. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer. 2008;8:186. doi:10.1186/1471-2407-8-186.CrossRefPubMedCentralPubMed

55.

Spira D, Neumeister H, Spira SM, Hetzel J, Spengler W, von Weyhern CH, et al. Assessment of tumor vascularity in lung cancer using volume perfusion CT (VPCT) with histopathologic comparison: a further step toward an individualized tumor characterization. J Comput Assist Tomogr. 2013;37:15–21. doi:10.1097/RCT.0b013e318277c84f.CrossRefPubMed

56.

Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013;23:2127–36. doi:10.1007/s00330-013-2821-2.CrossRefPubMed

57.

Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009;193:1090–6. doi:10.2214/ajr.08.1367.CrossRefPubMed

58.

Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med. 2010;16:508–15. doi:10.1016/j.molmed.2010.08.003.CrossRefPubMed

59.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

60.

Holland JP, Cumming P, Vasdev N. PET of signal transduction pathways in cancer. J Nucl Med. 2012;53:1333–6. doi:10.2967/jnumed.112.105387.CrossRefPubMed

61.

Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40:558–66. doi:10.1016/j.ctrv.2013.10.001.CrossRefPubMed

62.

Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer. 2014;110:363–8. doi:10.1038/bjc.2013.705.CrossRefPubMedCentralPubMed

63.

Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34. doi:10.1158/1940-6207.capr-10-0328.CrossRef

64.

Trigonis I, Koh PK, Taylor B, Tamal M, Ryder D, Earl M, et al. Early reduction in tumour [(18)F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. Eur J Nucl Med Mol Imaging. 2014;41:682–93. doi:10.1007/s00259-013-2632-3.CrossRefPubMedCentralPubMed

65.

Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, et al. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2011;52:1871–7. doi:10.2967/jnumed.111.094458.CrossRefPubMed

66.

Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701–8. doi:10.1200/jco.2010.32.4939.CrossRefPubMed

67.

Lee SJ, Yeo JS, Lee HJ, Lee EJ, Kim SY, Jang SJ, et al. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:1327–35. doi:10.1007/s00259-014-2712-z.CrossRefPubMed

68.

Putora PM, Müller J, Borovicka J, Plasswilm L, Schmidt F. Relevance of incidental colorectal FDG-PET/CT-enhanced lesions. Onkologie. 2013;36:200–4. doi:10.1159/000350302.CrossRefPubMed

69.

Mishani E, Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med. 2009;50:1199–202. doi:10.2967/jnumed.109.062117.CrossRefPubMed

70.

Miao Z, Ren G, Liu H, Qi S, Wu S, Cheng Z. PET of EGFR expression with an 18F-labeled affibody molecule. J Nucl Med. 2012;53:1110–8. doi:10.2967/jnumed.111.100842.CrossRefPubMedCentralPubMed

71.

Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009;69:873–8. doi:10.1158/0008-5472.can-08-3118.CrossRefPubMed

72.

Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A. 2011;108:1603–8. doi:10.1073/pnas.1010744108.CrossRefPubMedCentralPubMed

73.

Pecking AP, Bellet D, Alberini JL. Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging. Clin Exp Metastasis. 2012;29:847–52. doi:10.1007/s10585-012-9501-5.CrossRefPubMed

74.

Staudacher AH, Al-Ejeh F, Fraser CK, Darby JM, Roder DM, Ruszkiewicz A, et al. The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®. EJNMMI Res. 2014;4:2. doi:10.1186/2191-219x-4-2.CrossRefPubMedCentralPubMed

75.

Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med. 2013;1:551–63. doi:10.1016/s2213-2600(13)70159-0.CrossRefPubMed

76.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. doi:10.1056/NEJMoa1003466.CrossRefPubMedCentralPubMed

77.

Neumann A, Hörzer H, Hillen N, Klingel K, Schmid-Horch B, Bühring HJ, et al. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother. 2013;62:1485–97. doi:10.1007/s00262-013-1454-2.CrossRefPubMed

78.

Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.CrossRefPubMed

79.

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9. doi:10.2967/jnumed.107.045864.CrossRefPubMed

80.

Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156–63. doi:10.1016/j.semradonc.2010.01.003.CrossRefPubMedCentralPubMed

81.

Bollineni VR, Wiegman EM, Pruim J, Groen HJ, Langendijk JA. Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev. 2012;38:1027–32. doi:10.1016/j.ctrv.2012.04.003.CrossRefPubMed

82.

Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol. 2010;97:172–5. doi:10.1016/j.radonc.2010.05.012.CrossRefPubMed

83.

Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, et al. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res. 2012;18:5427–37. doi:10.1158/1078-0432.ccr-12-0214.CrossRefPubMed

84.

Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 2010;37:911–6. doi:10.1016/j.nucmedbio.2010.06.004.CrossRefPubMed

85.

Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770–6. doi:10.2967/jnumed.109.066837.CrossRefPubMed

86.

Ippolito D, Capraro C, Guerra L, De Ponti E, Messa C, Sironi S. Feasibility of perfusion CT technique integrated into conventional 18FDG/PET-CT studies in lung cancer patients: clinical staging and functional information in a single study. Eur J Nucl Med Mol Imaging. 2013;40:156–65. doi:10.1007/s00259-012-2273-y.CrossRefPubMed

87.

Sauter AW, Winterstein S, Spira D, Hetzel J, Schulze M, Mueller M, et al. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med. 2012;53:521–9. doi:10.2967/jnumed.111.097865.CrossRefPubMed

88.

Mankoff DA, Dunnwald LK, Partridge SC, Specht JM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res. 2009;15:5294–6. doi:10.1158/1078-0432.ccr-09-1448.CrossRefPubMedCentralPubMed

89.

Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:22–8. doi:10.1007/s00259-005-1932-7.CrossRefPubMed

90.

Sauter AW, Spira D, Schulze M, Pfannenberg C, Hetzel J, Reimold M, et al. Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40:677–84. doi:10.1007/s00259-012-2318-2.CrossRefPubMed

91.

van Elmpt W, Das M, Hüllner M, Sharifi H, Zegers CM, Reymen B, et al. Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiother Oncol. 2013;109:65–70. doi:10.1016/j.radonc.2013.08.032.CrossRefPubMed

92.

Wehrl HF, Sauter AW, Judenhofer MS, Pichler BJ. Combined PET/MR imaging – technology and applications. Technol Cancer Res Treat. 2010;9:5–20.CrossRefPubMed

93.

Schwenzer NF, Schraml C, Müller M, Brendle C, Sauter A, Spengler W, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging – pilot study. Radiology. 2012;264:551–8. doi:10.1148/radiol.12111942.CrossRefPubMed

94.

Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, et al. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Investig Radiol. 2013;48:247–55. doi:10.1097/RLI.0b013e31828d56a1.CrossRef

95.

Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Takahashi M, Van Cauteren M, et al. T2* measurements of 3-T MRI with ultrashort TEs: capabilities of pulmonary function assessment and clinical stage classification in smokers. AJR Am J Roentgenol. 2011;197:W279–85. doi:10.2214/AJR.10.5350.CrossRefPubMed

96.

Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data – methods and preliminary results. Radiology. 2012;264:387–96. doi:10.1148/radiol.12111607.CrossRefPubMedCentralPubMed

Title: Image-derived biomarkers and multimodal imaging strategies for lung cancer management
Authors: Alexander W. Sauter
Nina Schwenzer
Mathew R. Divine
Bernd J. Pichler
Christina Pfannenberg
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2974-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Image-derived biomarkers and multimodal imaging strategies for lung cancer management

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Biomarkers in preclinical cancer imaging

Radiopharmaceuticals as probes to characterize tumour tissue

Functional MRI and CT biomarkers in oncology

Imaging biomarkers in primary brain tumours

PET imaging biomarkers in head and neck cancer

Imaging biomarkers in oncology: we can get more from what we see